Comparative efficacy and safety of first-line immunotherapy- and targeted therapy-based regimens for advanced gastric and gastroesophageal junction cancer: a network meta-analysis.
BACKGROUND: The optimal first-line immunotherapy- or targeted therapy-based regimen for advanced gastric cancer (GC) and gastroesophageal junction cancer (GEJC) remains uncertain, largely because direct head-to-head comparisons are limited. In safety analyses, EGFR-targeted agents showed relatively favorable profiles in selected outcomes.
BACKGROUND: The optimal first-line immunotherapy- or targeted therapy-based regimen for advanced gastric cancer (GC) and gastroesophageal junction cancer (GEJC) remains uncertain, largely because direct head-to-head comparisons are limited. In safety analyses, EGFR-targeted agents showed relatively favorable profiles in selected outcomes.
What the study was
- Study design
- Meta-analysis
- Sample size
- 10808
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- BMC cancer
Why it surfaced
High-priority Novel therapeutics: immunotherapy, CAR-T, targeted therapy study: promising preliminary signal warrants immediate pipeline escalation.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.